Search result

Vacancy: NHS Research Scotland Portfolio Manager

Due to secondment of the current post holder, Tayside Medical Science Centre (TASC) is seeking to appoint a  NHS Research Scotland Portfolio Manager on a fixed term basis for one year, with possible option to extend to 31 March 2027 The NRS Portfolio Manager is responsible for the coordination and delivery of the local portfolio of clinical research activity within NHS Tayside. The Portfolio Manager also has national responsibility for six NRS Specialties; Oral and Dental, Metab...

View Page

Further updates to model contract agreements for NHS and health and social care organisations announced

Commercial agreements and guidance published in December 2023 have been updated by the Four Nations Contracts Leads following feedback from commercial sponsors, Contract Research Organisations and the NHS The Health Research Authority (HRA) have updated the following suite of agreements as part of the

View Page

Scotland’s diverse volunteers urged to Be Part of Research on International Clinical Trials Day

NHS Research Scotland (NRS) is proud to be supporting International Clinical Trials Day (20 May) with this year’s theme of ‘Rethinking Clinical Trials: Inclusivity in Practice’ encouraging more diverse participation The day is dedicated to celebrating clinical research and research enabled innovation around the world and acknowledges the first randomised clinical trial conducted in May 1747 by Scottish physician James Lind. NRS believes that research is the s...

View Page

Health Research and Innovation Conference set to mark ‘pivotal moment’ for new era in Scottish care

The return of Scotland’s Health Research and Innovation Conference is set to mark ‘a pivotal moment in accelerating a new era of progressive thinking’ for the country’s ambitions Scotland’s Health Research and Innovation Conference will take place on Thursday 23 October at the Edinburgh International...

View Page

‘VPAG boost is ultimately about better patient outcomes across Scotland and realising true value’

The Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) must ultimately be about realising true value for the benefit of patients, says NHS Research Scotland (NRS) Last year, it was announced that £100m in public-private investment from pharmaceutical companies would deliver 20 research hubs across the UK as part of the wider £400 million VPAG scheme. Under its accompanying investment programme, Commercial Research Delivery Centres (CRDCs) will...

View Page

Scottish Cross-Sector Hub set for second gathering after launch success

The Academy of Medical Sciences Scotland Cross-Sector Hub is inviting attendees to its second event after a successful launch in March The free to attend event, taking place at the COSLA Conference Centre in Edinburgh on Wednesday 4 June, and hosted by NHS Research Scotland (NRS), will place its prime focus on research and innovation in ‘Precision Medicine and Precision Popu...

View Page

NHS Research Scotland Primary Care Network Bursary Scheme opens up ‘world of conference opportunities’

Applications are now being invited for a conference bursary which has been made available for a fourth year by the NHS Research Scotland (NRS) Primary Care Network The scheme encourages GP trainees and medical students to apply, allowing recipients to attend a national Primary Care conference and deepen their research knowledge while helping to potentially shape future clinical approaches. Th...

View Page

Updated expectations for agreements used by commercial sponsors now published

The Health Research Authority (HRA) has today (Monday 28 April 2025) announced the publication of a new model Commercial Chief Investigator Agreement (mCCIA), and model Confidential Disclosure Agreements (mCDA), both of which are expected to be used without modification Announced in an edition of the organisation’s HRA Now bulletin, the guidance is expected to be of most use to Commercial Spon...

View Page

Ninewells Hospital recruits first patient for trial aimed at improving treatment of specific leukaemia

The University of Dundee and NHS Tayside has successfully recruited the first patient in the UK to a clinical trial that aims to improve treatments for a sub-group of patients affected by an aggressive blood cancer Led by Cardiff University, the OPTIMISE-FLT3 study officially opened for recruitment on 19 February, marking what the Co-Chief Investigators have called “a significant step forward” in evaluating new treatment strategies for FLT3-mutu...

View Page

New UK clinical trials regulations signed into law — implementation period begins

New rules for running clinical trials in the UK have now been officially been signed into law The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024 were formally signed by Wes Streeting MP, Secretary of State for Health and Social Care yesterday. Yesterday (10 April 2025) marks the start of a 12-month implementation period before the amended regulations come fully into force on 10 April 2026. The updated regulations will soon be available on th...

View Page